MedTrace Logo

Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study

NCT05423275 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-12-09

No results posted yet for this study

Summary

Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of "maintenance" antidepressant treatment, after patients achieve symptom remission, to prevent relapse but many people stop antidepressants too soon relapse into another depressive episode. We will test non-medication treatments, negative ion therapy and light therapy, to see they can substitute for antidepressants to prevent relapse. This is a "feasibility" study to see if participants use study treatments properly, before doing a larger, definitive trial. In this 28-week study, 100 participants with MDD who are in remission with antidepressants will be treated with light therapy or negative ion therapy (with half of devices active and half inactive) while slowly discontinuing the antidepressant, and monitored for relapse.

Conditions

  • Major Depressive Disorder, Recurrent, in Remission

Interventions

DEVICE

Negative ion therapy

Negative ion generator

DEVICE

Light therapy

Fluorescent light box

Sponsors & Collaborators

  • University of Toronto

    collaborator OTHER

  • Université de Montréal

    collaborator OTHER

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • McMaster University

    collaborator OTHER

  • Ontario Brain Institute

    collaborator OTHER

  • Centre for Addiction and Mental Health

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Raymond W Lam, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-13
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05423275 on ClinicalTrials.gov